About BioCentriq
BioCentriq is a full service CDMO. We offer product development and clinical production for cell and gene therapies. BioCentriq was founded in 2019 and launched our pilot development plant at the same time. In October of 2020 we completed the validation of our GMP center and opened the doors for clinical manufacturing.
Our mission is to accelerate the advancement of cell and gene therapies by improving the efficiency and effectiveness of manufacturing processes and technologies. To support that mission, we also offer custom and standard workforce development programs to help close the skills gap that exists in the industry today.
Learn More
Want to learn more?
Request our full capabilities brochure!
Dr. Joanne BeckChief Operating Officer, Boston Pharmaceuticals
NJII has made significant progress in the area of regenerative medicine and we are very excited about their new center and the opportunity for companies of varying sizes to leverage the center for cell and gene therapy development and manufacturing projects as well as workforce development.
Jose Lozano, CEOPresident & CEO, ChooseNJ
“This is a complete game-changer for New Jersey. BioCentriq is a state-of-the-art facility that will attract cutting-edge companies and innovation from around the world.”
Peter Marks, Center For Biologics Evaluation and Research (CBER)U.S. Food and Drug Administration (FDA)
“Right now, the throughput for cell and gene therapies is limited. We don’t fully understand how to manufacture therapies in a reproducible manner, from scaling up and scaling out. This type of facility will hopefully get us to the place where that will be possible.”
Recent Updates
BioCentriq™ and Kytopen® Partner to Demonstrate Impact of Transformative Technology on Cell Therapy Manufacturing
March 23, 2021Partnership Enhances Development Capacity of Tevogen Bio’s Proprietary Targeted T cell Therapy for COVID-19
March 15, 2021Cutting-Edge Cell & Gene Therapy Manufacturing Center, BioCentriq™ Opens in Newark, New Jersey
October 29, 2020Choosing a CDMO: Top 10 Intangibles Biotech Firms Should Consider
October 22, 2020Get In Touch
Please use the form below to get in touch with a member of our team.